Terms ending in 2042
Every in-force patent on Hoffmann-La Roche Inc.'s record whose computed term ends in 2042, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,799,185 | Anti-Hbv Antibodies and Methods of Use In force · High confidence | Hoffmann-La Roche Inc. | In force | High confidence | |
| US 12,742,848 | Beacon-Based Location Detection In force · Medium confidence | Hoffmann-La Roche Inc. | In force | Medium confidence | |
| US 12,180,196 | Novel Azetidine-Substituted Pyridine and Pyrazine Compounds as Inhibitors of Cannabinoid Receptor 2 In force · High confidence | Hoffmann-La Roche Inc. | In force | High confidence | |
| US 12,139,506 | Process for the Preparation of Galnac Phosphoramidite Epimers In force · High confidence | Hoffmann-La Roche Inc. | In force | High confidence | |
| US 12,195,470 | 7-Phenoxy-n-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-amine Derivatives and Related Compounds as Gamma-Secretase Modulators for the Treatment of Alzheimer's Disease In force · High confidence | Hoffmann-La Roche Inc. | In force | High confidence | |
| US 12,174,184 | Target Interference Suppressed Anti-Drug Antibody Assay In force · High confidence | Hoffmann-La Roche Inc. | In force | High confidence | |
| US 12,322,508 | Intelligent Workflow Analysis for Treatments Using Exposable Cloud-Based Registries In force · High confidence | Hoffmann-La Roche Inc. | In force | High confidence | |
| US 11,898,145 | Enhanced Oligonucleotides for Inhibiting RTEL1 Expression In force · High confidence | Hoffman-la Roche Inc. | In force | High confidence | |
| US 12,497,621 | Oligonucleotides for Modulating RTEL1 Expression In force · High confidence | Hoffmann-La Roche Inc. | In force | High confidence | |
| US 12,462,938 | Machine-Learning Model for Generating Hemophilia Pertinent Predictions Using Sensor Data In force · High confidence | F. Hoffmann-La Roche AG | In force | High confidence | |
| 62 more term ends in 2042 · Pro | |||||
10 of 72 patents shown. Soonest term end first, then patent number.
Pro members see all 72.
66 of these are in force and held by Hoffmann-La Roche Inc..
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.